jRCT2031200407: Phase I study of SOF10 in patients with advanced solid tumors |
|
|
| Active, not recruiting | 1 | | Japan | RG6440 - Roche, Tecentriq (atezolizumab) - Roche | Chugai Pharmaceutical Co., Ltd. | Solid Tumor | | | | |
NCT05867121: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors |
|
|
| Active, not recruiting | 1 | 102 | Europe, Japan, US, RoW | RO7496353, SOF 10, Atezolizumab, RO554126 7; Tecentriq, Capecitabine, S-1, Tegafur/Gimeracil/Oteracil potassium, Nivolumab, Oxaliplatin, Nab-paclitaxel, Gemcitabine | Genentech, Inc., Chugai Pharmaceutical Co. | Metastatic Solid Tumor, Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma | 12/25 | 12/25 | | |
